On the other hand, tissue-restricted FXR agonists can improve insulin sensitivity and reduce hepatic steatosis in HFD mice and non-diabetic NAFLD patients (Carino et al., 2017; Traussnigg et al., 2021). Here, NR1H4 is linked to Hepatic steatosis.